Product Description
Mechanisms of Action: CYP17 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Prostate Cancer
Phase 2: Adenocarcinoma|Prostate Cancer|Breast Cancer|Granulosa Cell Tumor
Phase 1: Prostate Cancer|Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RTOG 1115 | P3 |
Active, not recruiting |
Prostate Cancer |
2021-11-01 |
|
| S1216 | P3 |
Active, not recruiting |
Prostate Cancer |
2021-05-18 |
|
| SCRI BRE 203 | P2 |
Completed |
Breast Cancer |
2021-05-01 |
|
| Greko II | P2 |
Terminated |
Granulosa Cell Tumor |
2017-01-11 |